The SLU-PP-332 patent is held through academic filings that cover the compound and its uses. Learn what it protects and how to check its current status.
A SLU-PP-332 patent covers the chemical structure of the compound and the specific uses claimed by its inventors, and rights to those filings are typically assigned to the academic institution where the research was performed. A patent filing does not mean SLU-PP-332 is approved, tested in humans, or legal to sell as a supplement. Patent status and regulatory status are two separate questions, and mixing them up is the most common mistake people make when they read about this molecule.
What Is SLU-PP-332?
SLU-PP-332 is an experimental small molecule that activates estrogen-related receptors (ERR alpha, ERR beta, and ERR gamma). Researchers describe it as a potential "exercise mimetic" because it has produced endurance and metabolic effects in rodents without training.
- Class: Synthetic ERR agonist, studied for metabolic and muscle-related effects.
- Preclinical findings: Mouse studies have linked it to improved running endurance, greater fatty acid oxidation, and changes in body composition.
- Human data: None published. SLU-PP-332 is not FDA-approved for any indication.
- Market status: Sold online as a "research chemical," usually with a not-for-human-consumption label.
Who Owns the Rights to SLU-PP-332?
Compounds like this almost always originate in university laboratories, and inventors are typically required to assign their rights to the institution. The school's technology transfer office then decides whether to license the patent family to a pharmaceutical company, launch a startup, or hold the rights.
That ownership structure matters for anyone tracking the molecule. A single university can control composition-of-matter claims, method-of-use claims, and follow-up compounds in one portfolio, which is why comparisons such as slu-pp-915 vs slu-pp-332 often trace back to the same patent family.
A compound's name is not a reliable guide to who owns it. Assignee records in patent databases are.
What Does a SLU-PP-332 Patent Actually Protect?
Patent claims define exactly what is protected, and a single utility patent can stack several claim types at once.
| Claim type | What it covers | Why it matters |
|---|---|---|
| Composition of matter | The molecule itself and its chemical structure | Blocks others from making or selling the exact compound |
| Genus or analog claims | Families of structurally related molecules | Can reach next-generation compounds such as SLU-PP-915 |
| Method of use | Specific applications, such as treating obesity or metabolic disease | Protects a use even when a different molecule is involved |
| Formulation | Dosage forms, salts, and delivery systems | Covers oral tablets, injectables, and other routes |
Broad genus claims are the reason a single filing can slow down competitors working on closely related ERR agonists. Narrow claims protect less but are easier to defend.
How to Check the SLU-PP-332 Patent Status
Patent status changes over time, so the only reliable answer comes from official databases rather than vendor websites. These resources are free:
- USPTO Patent Public Search and Patent Center — search the compound name, the inventor names, and the assignee institution.
- Google Patents — the easiest way to read full text and follow patent families.
- Espacenet (EPO) and WIPO PATENTSCOPE — international equivalents covering European and PCT filings.
Applications usually publish about 18 months after the earliest filing date, and applications that have not yet published will not appear anywhere. Utility patents in the United States generally last 20 years from the earliest non-provisional filing date, so a compound first filed in the early 2020s would not enter the public domain until the 2040s.
Patent Status vs. Legal Status: What Buyers Get Wrong
A patent is a right to exclude others, not a permission slip. Selling a patented compound without a license can create infringement exposure even when the label says "research use only."
Regulatory status is separate again. SLU-PP-332 is not FDA-approved for human use, no human trials have been published, and there is no validated slu-pp-332 dosage. Because human data are absent, any discussion of slu-pp-332 side effects is speculative, and questions about slu-pp-332 oral vs injection usually reflect differences in animal study designs rather than a clinical protocol.
| Compound | Category | FDA-approved for human use | Typical market listing |
|---|---|---|---|
| SLU-PP-332 | Synthetic ERR agonist | No | Research chemical |
| SLU-PP-915 | Related ERR agonist reported in follow-up literature | No | Research chemical |
| MOTS-c | Mitochondrial-derived peptide | No | Research chemical |
Readers weighing options like slu-pp-332 vs mots-c are comparing mechanisms studied in animals, not approved therapies. Vendor labeling and marketing rarely mention patent ownership, FDA status, or the absence of human safety data.
Key Takeaways for Researchers and Buyers
- A SLU-PP-332 patent protects the chemical structure and claimed uses; it does not make the compound safe or legal for human use.
- Patent rights for SLU-PP-332 are generally held by the university or research institution where it was invented, not by online sellers.
- SLU-PP-332 is not FDA-approved for human use in the United States.
- Utility patents in the United States generally last 20 years from the earliest non-provisional filing date.
- Reported slu-pp-332 benefits come from rodent studies and have not been confirmed in humans.
Patent filings, licensing deals, and startup announcements are usually the earliest public signal that a research compound is moving toward development. None of those events replace clinical trials. Because no human safety data exist, anyone considering a research compound for personal use should discuss it with a licensed healthcare professional instead of relying on vendor claims or animal results.
Frequently Asked Questions
Is SLU-PP-332 patented in the United States?
The compound and its uses have been the subject of patent filings by academic researchers, and patents in this space are typically assigned to the university or research institute rather than to individuals. Because applications can stay unpublished for 18 months and patent families differ by country, the only reliable way to confirm current status is to search the USPTO, Espacenet, and WIPO databases directly.
When would a SLU-PP-332 patent expire?
US utility patents generally expire 20 years after the earliest non-provisional filing date, so a compound first filed in the early 2020s would not enter the public domain until the 2040s. Patent term adjustments, terminal disclaimers, and lapsed maintenance fees can change the actual end date. Check each patent's filing date and status in USPTO Patent Center for an accurate answer.
Does a SLU-PP-332 patent mean the compound is approved for human use?
No. Patents are granted for novelty and utility, and they say nothing about safety or FDA approval. SLU-PP-332 has not been approved by the FDA for any human indication, and no human clinical trials have been published. Talk with a healthcare professional before using any research chemical.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.